Key result
Acute intravenous verapamil was well tolerated in infants with hypertrophic cardiomyopathy, reducing the left ventricular outflow tract gradient from 48.2 to 28.4 mmHg.
Why the study?
Does verapamil improve haemodynamics and clinical status in infants with hypertrophic cardiomyopathy?
Population
22 infants with an echocardiographic diagnosis of hypertrophic cardiomyopathy.
Design
Cohort
Follow-up
up to 16 years (1980-1996)
Authors
Loading...
Should not yet change practice in infant HCM; leaves open verapamil's role pending randomized data.
Cohort (n=22)
No
Does verapamil improve haemodynamics and clinical status in infants with hypertrophic cardiomyopathy?
Verapamil is well tolerated acutely in infants with hypertrophic cardiomyopathy and reduces left ventricular outflow tract obstruction, with a trend towards long-term clinical improvement.
Moran et al. (1998) conducted a cohort in Hypertrophic cardiomyopathy (n=22). Verapamil was evaluated on Safety and efficacy (acute haemodynamic effects and chronic clinical outcomes). Acute intravenous verapamil was well tolerated in infants with hypertrophic cardiomyopathy, reducing the left ventricular outflow tract gradient from 48.2 to 28.4 mmHg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: